Tirzepatide

Tilposide is a novel dual receptor agonist of glucagon like peptide-1 receptor (GLP-1) and glucose dependent insulinotropic peptide (GIP), administered once a week. GLP-1 and GIP both belong to enterotropin, which is a peptide secreted by the human gastrointestinal mucosa. The former can bind to receptors on pancreatic islet cells and stimulate insulin secretion, thereby producing hypoglycemic effects. It can also delay gastric emptying and inhibit appetite, thereby controlling weight; The latter has functions such as inhibiting gastric acid and pepsin secretion, stimulating insulin release, inhibiting gastric peristalsis and emptying, and can supplement the action of GLP-1 receptor agonists.